GR1008531B - Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη - Google Patents
Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινηInfo
- Publication number
- GR1008531B GR1008531B GR20140100157A GR20140100157A GR1008531B GR 1008531 B GR1008531 B GR 1008531B GR 20140100157 A GR20140100157 A GR 20140100157A GR 20140100157 A GR20140100157 A GR 20140100157A GR 1008531 B GR1008531 B GR 1008531B
- Authority
- GR
- Greece
- Prior art keywords
- atomoxetine hydrochloride
- oral solution
- maltitol
- xylitol
- solutions
- Prior art date
Links
- 229960002828 atomoxetine hydrochloride Drugs 0.000 title abstract 2
- LUCXVPAZUDVVBT-UNTBIKODSA-N atomoxetine hydrochloride Chemical compound Cl.O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C LUCXVPAZUDVVBT-UNTBIKODSA-N 0.000 title abstract 2
- 229940100688 oral solution Drugs 0.000 title 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 abstract 2
- 239000000845 maltitol Substances 0.000 abstract 2
- 235000010449 maltitol Nutrition 0.000 abstract 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 abstract 2
- 229940035436 maltitol Drugs 0.000 abstract 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 150000005846 sugar alcohols Polymers 0.000 abstract 2
- 239000000811 xylitol Substances 0.000 abstract 2
- 235000010447 xylitol Nutrition 0.000 abstract 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 abstract 2
- 229960002675 xylitol Drugs 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 abstract 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 abstract 1
- 239000004376 Sucralose Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 235000001465 calcium Nutrition 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229930188195 rebaudioside Natural products 0.000 abstract 1
- 229940013618 stevioside Drugs 0.000 abstract 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 abstract 1
- 235000019202 steviosides Nutrition 0.000 abstract 1
- 235000019408 sucralose Nutrition 0.000 abstract 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Πόσιμα υδατικά διαλύματα που περιέχουν υδροχλωρική ατομοξετίνη ως δραστικό συστατικό και έναν υγρό φορέα που περιέχει ξυλιτόλη, μαλτιτόλη και ένα γλυκαντικό που επιλέγεται από την ομάδα που αποτελείται από τη σουκραλόζη, τη σακχαρίνη, τη νατριούχα σακχαρίνη ή την ασβεστούχα σακχαρίνη, την στεβιοσίδη και την ρεμπαουδιοσίδη. Το pΗ του διαλύματος ρυθμίζεται στην περιοχή από 3.5 έως 4.5. Τα διαλύματα της παρούσας εφεύρεσης είναι εύγεστα, ακόμη και κατά την απουσία περαιτέρω πολυϋδρικών ή σακχαρούχων αλκοολών, πλέον της ξυλιτόλης και μαλτιτόλης.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20140100157A GR1008531B (el) | 2014-03-21 | 2014-03-21 | Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη |
| EP14726544.1A EP3003384B1 (en) | 2014-03-21 | 2014-05-02 | Oral solution comprising atomoxetine hydrochloride |
| ES14726544.1T ES2617252T3 (es) | 2014-03-21 | 2014-05-02 | Solución oral que comprende clorhidrato de atomoxetina |
| PCT/EP2014/059020 WO2015144255A1 (en) | 2014-03-21 | 2014-05-02 | Oral solution comprising atomoxetine hydrochloride |
| PT147265441T PT3003384T (pt) | 2014-03-21 | 2014-05-02 | Solução oral contendo cloridrato de atomoxetina |
| PL14726544T PL3003384T3 (pl) | 2014-03-21 | 2014-05-02 | Roztwór doustny zawierający chlorowodorek atomoksetyny |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20140100157A GR1008531B (el) | 2014-03-21 | 2014-03-21 | Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR1008531B true GR1008531B (el) | 2015-07-13 |
Family
ID=50828874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20140100157A GR1008531B (el) | 2014-03-21 | 2014-03-21 | Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3003384B1 (el) |
| ES (1) | ES2617252T3 (el) |
| GR (1) | GR1008531B (el) |
| PL (1) | PL3003384T3 (el) |
| PT (1) | PT3003384T (el) |
| WO (1) | WO2015144255A1 (el) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1009883B (el) * | 2019-06-07 | 2020-12-11 | Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας Και Αναπτυξης Α.Ε. | Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν υδροχλωρικη νορτριπτυλινη |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726473A (zh) * | 2016-03-31 | 2016-07-06 | 北京万全德众医药生物技术有限公司 | 托莫西汀或其可药用盐口服溶液及其制备方法 |
| CN106727291B (zh) * | 2016-12-06 | 2020-02-11 | 山东达因海洋生物制药股份有限公司 | 一种盐酸托莫西汀口服溶液及其制备方法 |
| US9855228B1 (en) | 2016-12-14 | 2018-01-02 | Taho Pharmaceuticals Ltd. | Oral solution comprising atomoxetine hydrochloride and methods thereof |
| CN112438949A (zh) * | 2019-09-05 | 2021-03-05 | 北京兴源联合医药科技有限公司 | 一种含钙补充剂的盐酸托莫西汀口服液及其制备方法 |
| CN111956607A (zh) * | 2020-09-25 | 2020-11-20 | 健民药业集团股份有限公司 | 盐酸托莫西汀口服溶液及其制备方法 |
| CN115778895B (zh) * | 2022-11-30 | 2024-04-26 | 江苏广承药业有限公司 | 一种盐酸托莫西汀口服溶液 |
| US20240197631A1 (en) * | 2022-12-07 | 2024-06-20 | OWP Pharmaceuticals, Inc. | Atomoxetine oral solution |
| WO2024156799A1 (en) * | 2023-01-27 | 2024-08-02 | Hyloris Developments Sa | Use of vitamin e tpgs as a taste masking agent for bitter drugs |
| CN119564602A (zh) * | 2025-02-08 | 2025-03-07 | 江苏长泰药业股份有限公司 | 一种盐酸托莫西汀口服溶液的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR75395B (el) | 1980-11-14 | 1984-07-13 | Lilly Co Eli | |
| WO2005065673A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Atomoxetine formulations |
| CA2568629A1 (en) * | 2004-07-22 | 2006-02-23 | Teva Pharmaceutical Fine Chemicals S.R.L. | Polymorphs of atomoxetine hydrochloride |
| US10624372B2 (en) * | 2009-08-28 | 2020-04-21 | Symrise Ag | Reduced-sweetener products, flavoring mixtures for said reduced-sweetener products and process for the production of products of this type |
-
2014
- 2014-03-21 GR GR20140100157A patent/GR1008531B/el active IP Right Grant
- 2014-05-02 PT PT147265441T patent/PT3003384T/pt unknown
- 2014-05-02 PL PL14726544T patent/PL3003384T3/pl unknown
- 2014-05-02 WO PCT/EP2014/059020 patent/WO2015144255A1/en not_active Ceased
- 2014-05-02 ES ES14726544.1T patent/ES2617252T3/es active Active
- 2014-05-02 EP EP14726544.1A patent/EP3003384B1/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1009883B (el) * | 2019-06-07 | 2020-12-11 | Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας Και Αναπτυξης Α.Ε. | Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν υδροχλωρικη νορτριπτυλινη |
Also Published As
| Publication number | Publication date |
|---|---|
| PL3003384T3 (pl) | 2017-06-30 |
| PT3003384T (pt) | 2017-01-18 |
| EP3003384A1 (en) | 2016-04-13 |
| EP3003384B1 (en) | 2016-10-26 |
| WO2015144255A1 (en) | 2015-10-01 |
| ES2617252T3 (es) | 2017-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR1008531B (el) | Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη | |
| PH12018501056A1 (en) | High intensity sweeteners | |
| EA201792224A1 (ru) | Композиции, содержащие ибрутиниб | |
| AR097213A1 (es) | Composiciones edulcorantes | |
| UA107570C2 (xx) | Безспиртовий водний розчин, що містить пропранолол | |
| UA105229C2 (uk) | Фармацевтичний склад | |
| MX2016007178A (es) | Glucosidos de triterpeno novedosos como edulcorantes o potenciadores de edulcorantes. | |
| HK1217294A1 (zh) | 4'-氟-2'-甲基取代的核苷衍生物 | |
| ZA202100339B (en) | Sweetening compositions | |
| MX2013010046A (es) | Administracion parenteral de tapentadol. | |
| NZ588602A (en) | Liquid formulation for deferiprone with palatable taste | |
| EP3228311A3 (en) | Pharmaceutical and nutraceutical compositions of abscisic acid | |
| PH12013501481A1 (en) | Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease | |
| RU2016138577A (ru) | Жидкая фармцевтическая композиция | |
| MX2016005998A (es) | Solucion de atomoxetina. | |
| ITTO20120776A1 (it) | Procedimento per mascherare l'amaro di un filtro uv | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| MX2011012114A (es) | Solucion farmaceutica bebible de telmisartan. | |
| WO2007138462A3 (en) | Aqueous oral formulations of risperidone | |
| UA111145C2 (uk) | Фармацевтична композиція | |
| WO2016022700A3 (en) | Tlr-independent small molecule adjuvants | |
| NZ717880A (en) | Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors | |
| ZA202100338B (en) | Sweetening compositions | |
| RU2015137671A (ru) | Профилактическое или терапевтическое лекарственное средство для лечения запора | |
| IN2014MU01179A (el) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PG | Patent granted |
Effective date: 20150901 |